Northwest Investment Counselors LLC Makes New $156,000 Investment in Bristol-Myers Squibb (NYSE:BMY)

Northwest Investment Counselors LLC bought a new stake in Bristol-Myers Squibb (NYSE:BMY) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,024 shares of the biopharmaceutical company’s stock, valued at approximately $156,000.

Several other institutional investors also recently made changes to their positions in BMY. Cassia Capital Partners LLC grew its position in Bristol-Myers Squibb by 2.9% in the 3rd quarter. Cassia Capital Partners LLC now owns 8,222 shares of the biopharmaceutical company’s stock worth $425,000 after purchasing an additional 235 shares during the last quarter. Toth Financial Advisory Corp boosted its position in shares of Bristol-Myers Squibb by 11.2% during the third quarter. Toth Financial Advisory Corp now owns 56,977 shares of the biopharmaceutical company’s stock worth $2,948,000 after buying an additional 5,719 shares during the period. Wealth Effects LLC grew its holdings in Bristol-Myers Squibb by 38.0% in the 3rd quarter. Wealth Effects LLC now owns 15,077 shares of the biopharmaceutical company’s stock worth $780,000 after buying an additional 4,150 shares in the last quarter. Castleview Partners LLC increased its position in Bristol-Myers Squibb by 765.7% in the 3rd quarter. Castleview Partners LLC now owns 49,441 shares of the biopharmaceutical company’s stock valued at $2,558,000 after acquiring an additional 43,730 shares during the period. Finally, Wealth Advisory Solutions LLC raised its stake in Bristol-Myers Squibb by 15.2% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 6,424 shares of the biopharmaceutical company’s stock valued at $332,000 after acquiring an additional 850 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on BMY. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Barclays upped their price objective on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. Jefferies Financial Group lifted their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Finally, Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a report on Thursday. They issued a “market perform” rating and a $56.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $53.20.

Bristol-Myers Squibb Stock Down 1.6 %

NYSE:BMY traded down $0.83 during trading hours on Monday, reaching $52.39. 2,872,739 shares of the stock were exchanged, compared to its average volume of 14,692,841. The stock has a market cap of $106.20 billion, a PE ratio of -17.17, a PEG ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $56.77. The firm has a 50 day moving average of $50.36 and a 200 day moving average of $46.33. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the business posted $1.75 EPS. On average, equities analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.58%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.